Acepodia
Biotechnology ResearchView the employees at
Acepodia-
Yi-Hung Ou Principal Scientist at Acepodia
-
New Taipei City, New Taipei City, Taiwan
-
Top 5%
sophia su ---
Taipei–Keelung Metropolitan area
-
Rising Star
Hao-Kang Li Preclinical Research Scientist at Acepodia-
Taipei City, Taipei City, Taiwan
-
Top 5%
Stephanie Chien Clinical Program Manager at Acepodia-
Rising Star
Steven Lin Acepodia Biotech QSC & QV Manager-
New Taipei City, New Taipei City, Taiwan
-
Rising Star
Overview
Acepodia is a clinical-stage biotechnology company developing innovative and highly effective cell therapies for cancer that are broadly accessible for patients. Leveraging its Antibody-Cell Conjugation (ACC) technology, the company links tumor-targeting antibodies to its proprietary immune effector cells, such as gamma delta T cells and natural killer (NK) cells to create novel antibody cell effector (ACE) therapies, which have increased binding strength against tumors that express low levels of tumor antigens. Acepodia is made up of seasoned leadership and scientific experts dedicated to advancing its robust pipeline of off-the-shelf ACE therapies with the potential to bring powerful, accessible cell therapies to a broad population of patients across a variety of solid tumors and hematologic cancers.
-